Analysts Issue Forecasts for KYMR FY2029 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Analysts at Brookline Capital Management issued their FY2029 EPS estimates for shares of Kymera Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann expects that the company will post earnings per share of ($6.44) for the year. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share.

KYMR has been the subject of several other research reports. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. UBS Group lowered their price objective on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Oppenheimer boosted their target price on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Friday, September 27th. Stephens started coverage on shares of Kymera Therapeutics in a report on Monday, November 18th. They issued an “overweight” rating and a $65.00 price target for the company. Finally, Morgan Stanley upped their price objective on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $55.38.

Kymera Therapeutics Trading Up 2.6 %

KYMR stock opened at $40.92 on Wednesday. The firm has a market cap of $2.65 billion, a PE ratio of -17.49 and a beta of 2.19. The stock has a 50-day moving average price of $44.34 and a 200-day moving average price of $43.94. Kymera Therapeutics has a 1-year low of $25.02 and a 1-year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. The business had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Kymera Therapeutics’s quarterly revenue was down 20.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.90) earnings per share.

Institutional Investors Weigh In On Kymera Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Values First Advisors Inc. bought a new position in shares of Kymera Therapeutics in the third quarter valued at approximately $61,000. Quarry LP purchased a new position in Kymera Therapeutics in the third quarter worth $95,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after purchasing an additional 504 shares during the period. Public Employees Retirement Association of Colorado purchased a new stake in shares of Kymera Therapeutics during the 2nd quarter valued at $139,000. Finally, Quest Partners LLC increased its position in shares of Kymera Therapeutics by 1,402.0% during the 2nd quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock valued at $156,000 after purchasing an additional 4,865 shares during the last quarter.

Insider Activity at Kymera Therapeutics

In other news, insider Ellen Chiniara sold 3,129 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $41.75, for a total value of $130,635.75. Following the completion of the sale, the insider now owns 54,826 shares in the company, valued at $2,288,985.50. This represents a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 15.82% of the stock is owned by insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.